Improvement of Liver Function in Liver Cirrhosis Patients After Autologous Mesenchymal Stem Cell Injection:a Phase I-II Clinical Trial

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-02-28

Study Completion Date

2009-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The methods for separation of mesenchymal stem cell were established in 2001. These cells can differentiate to osteocytes, hepatocytes, chondrocytes, myocytes and etc,. In this study the investigators try to separate mesenchymal stem cell from end stage liver disease, then these cells will be differentiated to progenitor of hepatocytes, finally , the investigators injected these cells into portal vein under ultrasound guide. The investigators determine the effects of injected cells in reestablishment of liver function.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Mesenchymal Stem Cell Transplantation in Decompensated Cirrhosis

NCT00476060

Cirrhosis

COMPLETED PHASE2

Effect of Mesenchymal Stem Cells-derived Exosomes in Decompensated Liver Cirrhosis

NCT05871463

Decompensated Liver Cirrhosis

UNKNOWN PHASE2

Transplantation of Autologous Mesenchymal Stem Cell in Decompensate Cirrhotic Patients With Pioglitazone

NCT01454336

Liver Fibrosis

COMPLETED PHASE1

Trial of Mesenchymal Stem Cell Transplantation in Decompensated Liver Cirrhosis

NCT03209986

Liver Cirrhosis

UNKNOWN NA

Human Menstrual Blood-derived Mesenchymal Stem Cells for Patients With Liver Cirrhosis

NCT01483248

Liver Cirrhosis Fibrosis Liver Disease +1 more

UNKNOWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Failure Cirrhosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

injection of progenitor of hepatocyte drived from Mesenchymal stem cell

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* MELD score of at least 10
* Patent portal vein on color Doppler examination of the liver
* Normal alpha-feto protein serum levels
* Age more than 18
* Filling inform consent by patients and first degree family members